RxDoctor Payments Data

Roy Norman, DO

Cardiovascular Disease · Tomball, TXNPI 1114296936

Payments from drug & device makers

$3,137in general payments, 2019–2025

Across 136 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Amgen$489
  • Novartis$146
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$140
  • Novo Nordisk$139
  • Johnson & Johnson$96
  • plus $307 from 10 others

What the payments were for

  • Food & beverage$3,137100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,137 in reported general payments places this provider in the 45th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$581,592
Medicare patients
374
Services billed
3,453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban247$251,284
XareltoRivaroxaban57$50,196
Repatha SureclickEvolocumab54$46,213
MounjaroTirzepatide26$36,892
Repatha PushtronexEvolocumab33$30,848
Metoprolol Succinate249$3,709
Ranolazine ErRanolazine28$3,189
Sumatriptan Succinate20$2,745
Atorvastatin Calcium251$2,071
ClopidogrelClopidogrel Bisulfate169$2,063
Rosuvastatin Calcium148$1,782
Amlodipine Besylate229$1,247
Isosorbide Mononitrate35$1,066
Amiodarone Hcl77$1,030
Flecainide Acetate23$815

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$96$50,19657 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Tomball

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →